Skip to main content
. 2023 Apr 28;15(5):1351. doi: 10.3390/pharmaceutics15051351

Figure 5.

Figure 5

Integrated evidence of DLQI 0/1. (1) Bimekizumab versus adalimumab. (2) Bimekizumab versus placebo.